달트로반
Daltroban
기본 정보
- CAS
105218-03-9- 표준 SMILES
O=C(O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1- InChIKey
IULOBWFWYDMECP-UHFFFAOYSA-N- 분자식
- C16H16ClNO4S
- 평균 분자량
- 353.8 g/mol
개요
Daltroban is a small molecule drug. Daltroban has a monoisotopic molecular weight of 353.05 Da.
이름 및 식별자
- 우선 이름
- Daltroban
- IUPAC
- 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid
- 현지명
- 달트로반
- 영어명
- daltroban
- 분자식
- C16H16ClNO4S
- 분자량
- 353.82054
이름 및 동의어
DALTROBAN79094-20-5BM-13505DaltrobanumSKF-96148SKF 96148BM 13.5052-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acidSK&F 96148DTXSID6046501S25VDY08ZCSKF96148
이름 더 보기
달트로반Benzeneacetic acid, 4-(2-(((4-chlorophenyl)sulfonyl)amino)ethyl)-
BM13505DTXCID40265012-(4-(2-((4-chlorophenyl)sulfonylamino)ethyl)phenyl)acetic acid4-(2-(4-Chlorophenylsulfonylamino)ethyl)phenylacetic acid4-(2-(4-Chlorobenzenesulfonylamino)ethyl)benzeneacetic acidRefChem:585160635-983-0BM 13505
데이터베이스 식별자
- CAS
105218-03-9- ChEMBL
CHEMBL71685- UNII
- S25VDY08ZC
- EC Number
- 635-983-0
- Nikkaji
- J153.943D
물성
구조 계산 물성
- XLogP
- 2.9
- 극성 표면적
- 91.9 Ų
- 수소 결합 공여자 수
- 2
- 수소 결합 수용자 수
- 5
- 회전 가능 결합 수
- 7
- 무거운 원자 수
- 23
- 형식 전하
- 0
- 복잡도
- 475
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
GHS 분류
GHS Classification
Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
유해성 정보
Hazard Classes and CategoriesSkin Irrit. 2 (100%)
화학 및 산업
약리 정보
MeSH Pharmacological Classification
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…